文献速递胸部肿瘤

早期非小细胞肺癌接受立体定向体部放疗患者的辅助全身治疗

Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy.
PubMed 文献 · J Thorac Oncol · 2018-11-29

该研究利用美国国家癌症数据库(2004-2013年)纳入11836例临床I-II期非小细胞肺癌患者,比较单纯立体定向体部放疗(SBRT)与SBRT后辅助化疗的总生存。结果显示,在T2bN0、T3N0及肿瘤≥4 cm且淋巴结阴性患者中,辅助化疗与更长的中位总生存相关;而肿瘤<4 cm且淋巴结阴性患者中,单纯SBRT组中位总生存更长。

要点

  • T2bN0患者:单纯SBRT中位OS 16.5个月 vs SBRT+辅助化疗24.2个月(p<.001)。
  • T3N0患者:单纯SBRT中位OS 13个月 vs SBRT+辅助化疗20.1个月(p<.001)。
  • 肿瘤≥4 cm且淋巴结阴性:单纯SBRT 15.9个月 vs 联合化疗19个月(p<.001)。

核心结论

  • 在T≥4 cm的早期NSCLC患者中,SBRT后辅助化疗与单纯SBRT相比与改善的总生存相关,类似于手术后所见。

研究设计与样本

  • 利用美国国家癌症数据库(National Cancer Database)识别2004年至2013年诊断为临床I-II期NSCLC的≥18岁患者,共11836例。
  • 采用Kaplan-Meier法估计总生存分布,log-rank检验比较不同治疗策略的生存分布。
  • 临床I期和II期按TNM分期细分,并在各亚组内用log-rank检验比较不同治疗策略的生存分布。

主要发现

  • T2bN0患者:单纯SBRT组中位OS为16.5个月(95%CI 14.1-20.1个月),SBRT+辅助化疗组为24.2个月(95%CI 18.8-33.3个月),p<.001。
  • T3N0患者:单纯SBRT组中位OS为13个月(95%CI 11.7-14.5个月),SBRT+辅助化疗组为20.1个月(95%CI 17.7-21.9个月),p<.001。
  • 肿瘤≥4 cm且淋巴结阴性患者:单纯SBRT组中位OS为15.9个月(95%CI 15.1-16.8个月),SBRT+化疗组为19个月(95%CI 17.9-20.8个月),p<.001。
  • 肿瘤<4 cm且淋巴结阴性患者:单纯SBRT组中位OS为28.5个月(95%CI 27.4-29.4个月),SBRT+化疗组为24.3个月(95%CI 22.8-26.1个月),p<.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic body radiation therapy (SBRT) is commonly used to treat nonsurgical patients with early-stage NSCLC. There are no prospective data on the role of adjuvant chemotherapy in this setting. METHODS: Patients (≥18 years) diagnosed with clinical stages I-II NSCLC from 2004 to 2013 were identified using the National Cancer Database (n = 11,836). The Kaplan-Meier method was used to estimate overall survival (OS) distributions and the log-rank test was used to compare distributions by treatment strategy. Clinical stages I and II were subdivided according to the TNM staging and log-rank tests was used to compare survival distributions by treatment strategy within each subgroup. RESULTS: In patients with T2bN0, median OS in the SBRT alone and SBRT plus adjuvant chemotherapy groups were 16.5 months versus 24.2 months, respectively (95% confidence interval [CI]: 14.1-20.1 months and 18.8-33.3 months, respectively; p < .001); whereas for T3N0, median OS times were 13 months and 20.1 months, respectively (95% CI: 11.7-14.5 mohths and 17.7-21.9 months, respectively; p < .001). For tumors 4 cm or larger and node-negative disease, median OS was 15.9 months in the SBRT-alone group, and 19 months in the SBRT-plus-chemotherapy group (95% CI: 15.1-16.8 months and 17.9-20.8 months, respectively; p < .001). For patients with tumors less than 4 cm and node-negative disease, the median OS was 28.5 months in the SBRT-alone group and 24.3 months in the SBRT-plus-chemotherapy group (95% CI: 27.4-29.4 months and 22.8-26.1 months, respectively; p < .001). CONCLUSIONS: SBRT followed by adjuvant chemotherapy was associated with improved OS in comparison with SBRT alone in patients with T greater than or equal to 4 cm, similar to that seen after surgery.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ernani V, Appiah AK, Marr A, et al. Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy. J Thorac Oncol. 2018. PMID: 30503890. doi:10.1016/j.jtho.2018.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。